AKT3 and prostate carcinoma: AKT1, AKT2, and AKT3 activating mutations are rare in prostate cancer (≤0.9%, predominantly in AKT1 at E17K), whereas AKT1, AKT2, and AKT3 high-level gene amplification that can increase AKT activity is more common, particularly in advanced disease (up to 4.5%, 2%, and 4.7% incidence respectively, Tables S1–S3).